ATE318596T1 - Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii - Google Patents
Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase iiInfo
- Publication number
- ATE318596T1 ATE318596T1 AT02718005T AT02718005T ATE318596T1 AT E318596 T1 ATE318596 T1 AT E318596T1 AT 02718005 T AT02718005 T AT 02718005T AT 02718005 T AT02718005 T AT 02718005T AT E318596 T1 ATE318596 T1 AT E318596T1
- Authority
- AT
- Austria
- Prior art keywords
- topoisomerase
- succinimide
- maleimide
- formula
- maleimide derivatives
- Prior art date
Links
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 title abstract 5
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 title abstract 5
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title abstract 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical class O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 title abstract 4
- 230000003197 catalytic effect Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229960002317 succinimide Drugs 0.000 title 1
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000824 cytostatic agent Substances 0.000 abstract 2
- 239000002574 poison Substances 0.000 abstract 2
- 231100000614 poison Toxicity 0.000 abstract 2
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100522 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE318596T1 true ATE318596T1 (de) | 2006-03-15 |
Family
ID=8160403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02718005T ATE318596T1 (de) | 2001-03-29 | 2002-03-27 | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1373494B1 (de) |
| AT (1) | ATE318596T1 (de) |
| AU (1) | AU2002249103A1 (de) |
| DE (1) | DE60209471D1 (de) |
| WO (1) | WO2002078679A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002322323A1 (en) | 2001-06-25 | 2003-01-08 | Massachusetts Institute Of Technology | Bioerodible conducting materials |
| ES2269975T3 (es) | 2002-02-21 | 2007-04-01 | Aprea Ab | Uso de compuestos de bajo peso molecular para preparar un medicamento util para tratar enfermedades mediadas por p53 mutante. |
| GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| KR100596360B1 (ko) * | 2003-07-15 | 2006-07-03 | 한국생명공학연구원 | 항암 활성을 갖는 신규 2-옥소-피페리딘 유도체(ⅰ)화합물을 포함하는 암 질환 치료를 위한 약학 조성물 |
| EP1663201A4 (de) * | 2003-07-15 | 2009-10-28 | Korea Res Inst Of Bioscience | Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| CN119039203A (zh) * | 2024-09-20 | 2024-11-29 | 上海信诺维生物医药有限公司 | 一类含有马来酰亚胺结构的化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| GB9605533D0 (en) * | 1996-03-15 | 1996-05-15 | Unilever Plc | Modified aluminosilicate |
| DE19838506C2 (de) * | 1998-05-04 | 2000-08-31 | Asta Medica Ag | Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen |
| JP2002527419A (ja) * | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類 |
| CA2367240C (en) * | 1999-03-12 | 2010-11-16 | Clinigen Group Plc | Treatment of accidental extravasation of anthracyclines |
| ATE322266T1 (de) * | 2000-05-15 | 2006-04-15 | Celgene Corp | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten |
-
2002
- 2002-03-27 AT AT02718005T patent/ATE318596T1/de not_active IP Right Cessation
- 2002-03-27 EP EP02718005A patent/EP1373494B1/de not_active Expired - Lifetime
- 2002-03-27 DE DE60209471T patent/DE60209471D1/de not_active Expired - Fee Related
- 2002-03-27 AU AU2002249103A patent/AU2002249103A1/en not_active Abandoned
- 2002-03-27 WO PCT/DK2002/000213 patent/WO2002078679A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1373494B1 (de) | 2006-03-01 |
| DE60209471D1 (de) | 2006-04-27 |
| WO2002078679A2 (en) | 2002-10-10 |
| WO2002078679A3 (en) | 2002-12-19 |
| EP1373494A2 (de) | 2004-01-02 |
| AU2002249103A1 (en) | 2002-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200400480A1 (ru) | N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы | |
| NO20080150L (no) | Inhibitorer av AKT-aktivitet | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| BR0114023A (pt) | Derivados de imidazol como inibidores de quinase raf | |
| ATE370139T1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
| BRPI0515500A (pt) | derivados piridazina para inibição de estearoil-coa-desaturase | |
| BRPI0515477A (pt) | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) | |
| TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| NO20061194L (no) | Mitotiske kinesininbibitorer | |
| WO2003049702A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| ATE556048T1 (de) | Prolinderivate und ihre verwendung als heilmittel | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| DE69922216D1 (de) | Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte | |
| EA200801611A1 (ru) | Противораковые комбинации | |
| DK1044197T3 (da) | Piperidinylsubstituerede pyridylalkan-, -alken- og -alkyncarboxamider som cytostatiske midler og immunosuppressive midler | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| ATE452884T1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| DE60209471D1 (de) | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii | |
| ATE302203T1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| NO20091495L (no) | Pyrazolopyrimidinderivat | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |